Somatropin

Somatropin is the International Nonproprietary Name for recombinant human growth hormone (rhGH), a 191-amino acid, single-chain, non-glycosylated polypeptide with a molecular weight of 22,124 daltons that is identical in primary sequence to the major circulating isoform of endogenous pituitary growth hormone encoded by the GH1 gene on chromosome 17q23.3. The compound was first produced by recombinant DNA technology at Genentech, Inc., where Goeddel et al. (1979) achieved direct expression of the human GH coding sequence in Escherichia coli [1], leading to the FDA approval of somatrem (methionyl-hGH, Protropin) in 1985 and of somatropin (authentic 191-amino acid sequence, Humatrope) in 1987. The transition from cadaveric pituitary-extracted growth hormone to recombinant production was driven by the identification in 1985 of Creutzfeldt-Jakob disease cases in recipients of pituitary-derived GH, a transmissible spongiform encephalopathy that resulted in the withdrawal of all pituitary-derived GH preparations worldwide [2, 3]. Somatropin acts through the growth hormone receptor (GHR), a single-pass transmembrane receptor of the type I cytokine receptor superfamily. Ligand binding induces receptor dimerization and rotational activation, transphosphorylation of the receptor-associated tyrosine kinase Janus kinase 2 (JAK2), and downstream activation of signal transducer and activator of transcription 5b (STAT5b), the mitogen-activated protein kinase (MAPK/ERK) cascade, and the phosphatidylinositol 3-kinase/Akt pathway [4, 5]. The dominant endocrine mediator of the growth-promoting action of somatropin is insulin-like growth factor 1 (IGF-1), synthesized principally in the liver in response to GH receptor activation and acting through the IGF-1 receptor on growth plate chondrocytes, skeletal muscle, and other target tissues [6]. Pharmacokinetics after subcutaneous injection are characterized by an absorption half-life of approximately 2 to 3 hours, a peak plasma concentration at 3 to 6 hours, a systemic bioavailability of approximately 70 to 80 percent, a volume of distribution approximating plasma volume (approximately 50 mL/kg), and an elimination half-life of 3 to 5 hours driven predominantly by renal and hepatic receptor-mediated clearance [7, 8]. Approved indications in the United States and the European Union include pediatric growth hormone deficiency, Turner syndrome, chronic renal insufficiency prior to transplantation, Prader-Willi syndrome, children born small for gestational age who fail to demonstrate catch-up growth, idiopathic short stature, SHOX gene haploinsufficiency, Noonan syndrome, adult growth hormone deficiency, and AIDS-associated wasting and cachexia [9, 10]. The compound is administered by daily subcutaneous injection at weight-based doses typically in the range of 0.024 to 0.067 mg/kg/day in pediatric indications and 0.1 to 0.8 mg/day (non-weight-based) in adult GH deficiency, with dose titration guided by serum IGF-1 concentration [10, 11]. Long-acting formulations including somapacitan (Sogroya, weekly subcutaneous) and lonapegsomatropin (Skytrofa, weekly subcutaneous) have been approved since 2020 as alternatives to daily somatropin for selected indications [12, 13]. The principal adverse events are dose-dependent and include peripheral edema, arthralgia, myalgia, carpal tunnel syndrome, and insulin resistance, all attributable to the physiological actions of growth hormone on sodium retention, connective tissue, and glucose metabolism [14]. Long-term safety surveillance through multinational registries (KIGS, GeNeSIS, HypoCCS, NCGS) encompassing more than 100,000 patient-years has not demonstrated a causal increase in de novo malignancy, recurrence of primary tumors, or cardiovascular mortality at replacement doses, though the data mandate continued vigilance in patients with active malignancy, proliferative diabetic retinopathy, or critical illness [15, 16, 17]. This monograph documents the chemistry and biosynthesis of somatropin; the growth hormone receptor signaling cascade in molecular detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology of the GH-IGF-1 axis; the clinical evidence base across all approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety-signal analysis; and a comparative assessment of five alternative growth-promoting or GH-axis compounds against somatropin on five competency standards.